Skip to main content

Day: January 8, 2021

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®

SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. “Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in...

Continue reading

FLYHT to Participate in MoneyShow January Virtual Expo

CALGARY, Alberta, Jan. 08, 2021 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “FLYHT”) announced today that management will participate in the MoneyShow January Virtual Expo which will be held virtually on January 12-14, 2021. Bill Tempany, Interim CEO of FLYHT, and Alana Forbes, CFO, are scheduled to host a virtual presentation on Tuesday, January 12 at 3:20 PM ET (1:20 PM MT), followed by a Q&A session. All existing and prospective shareholders are invited to listen to the webcast and to visit the virtual booth to learn more about the Company.More information on the MoneyShow and free registration for the webcast can be found at www.moneyshowvirtualevent.com, or by contacting FLYHT’s IR team at flyht@fnkir.com.About FLYHT Aerospace Solutions Ltd.FLYHT provides airlines with...

Continue reading

CareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has agreed to acquire TransChart LLC, an Ohio-based provider of electronic health record software supporting the needs of US transplant centers. The transaction is expected to close in January 2021.TransChart provides electronic medical record software to hospitals throughout the United States to care for patients who have or may need an organ transplant. TransChart builds on the CareDx digital offerings, which include Ottr transplant electronic medical record software and XynQAPI transplant quality management solutions. This...

Continue reading

Fitch Ratings Upgrades the Rating of Bonds issued by Realkredit Danmark A/S from Capital Centre T

Company announcement No. 3/2021Fitch Ratings Upgrades the Rating of Bonds issued by Realkredit Danmark A/S from Capital Centre TToday, Fitch Ratings announced their AAA rating of mortgage covered bonds (SDRO’s) issued from Realkredit Danmark’s Capital Centre T, an upgrade from AA+.Realkredit Danmark is the only specialised mortgage bank in Denmark that is rated by three rating agencies. Today’s announcement implies that both Fitch Ratings, S&P Global and Scope Ratings have assigned their highest possible rating, AAA to Realkredit Danmark’s rated bonds.The ratings emphasise the robust credit quality and resilient profitability of Realkredit Danmark. Realkredit Danmark believes the announced rating to confirm investors’ trust in Realkredit Danmark and the Danish mortgage banking system.Yours faithfully,The Executive Board of Realkredit...

Continue reading

Fitch Ratings opgraderer ratingen af obligationerne i Realkredit Danmark A/S’ kapitalcenter T

Selskabsmeddelelse nummer 3/2021Fitch Ratings opgraderer ratingen af obligationerne i Realkredit Danmark A/S’ kapitalcenter T Fitch Ratings har i dag meddelt AAA rating af særligt dækkede realkreditobligationer (SDRO) udstedt fra Realkredit Danmarks kapitalcenter T mod hidtil AA+.Realkredit Danmark er som det eneste realkreditinstitut i Danmark ratet af tre ratingbureauer. Dagens meddelelse fra Fitch Ratings betyder, at både Fitch Ratings, S&P Global og Scope Ratings giver deres højeste rating, AAA til Realkredit Danmarks ratede obligationer.Disse ratings understreger Realkredit Danmarks robuste kreditkvalitet og solide indtjeningsevne. Realkredit Danmark vurderer, at den meddelte rating vil bekræfte investorerne i deres tillid til Realkredit Danmark og det danske realkreditsystem.Med venlig hilsenDirektionenEventuel henvendelse...

Continue reading

Tryg to postpone its Capital Markets Day to the autumn 2021

Following the announced cash offer for RSA Insurance Group Plc on 18th November 2020 and pending approval from regulatory authorities, Tryg has decided to postpone the Capital Markets Day originally planned for 28th January 2021.As communicated previously, the intended acquisition of certain RSA’s Nordic assets is deemed transformational for Tryg and it will have a profound impact on the company’s operational and financial performance. Tryg has therefore decided to postpone its Capital Markets Day to the autumn when Tryg expect to have obtained the approval of the acquisition from the relevant authorities.A new date will be announced in due course.AttachmentTryg to postpone its Capital Markets Day to the autumn 2021

Continue reading

Jiayin Group Inc. Announces Changes in Management

SHANGHAI, China, Jan. 08, 2021 (GLOBE NEWSWIRE) — Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced that Mr. Chunlin Fan tendered his resignation from the position as the Company’s Chief Financial Officer due to personal reasons, effective from January 8, 2021. Mr. Dinggui Yan, the Founder, Director and Chief Executive Officer, expressed appreciation for Mr. Fan’s contributions to the development of the Company on behalf of the board of directors and management team of the Company.Ms. Bei Bai, the current Financial Controller of the Company, and Ms. Jin Chen, the current Investment and Finance Director of the Company, have been appointed as the Co-Chief Financial Officers of the Company, effective from January 8, 2021.Ms. Bai, the current Financial Controller, joined...

Continue reading

OraSure Technologies Announces 2021 Annual Meeting Date

BETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 18, 2021. The record date for the Meeting will be March 26, 2021. Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2021 Annual Meeting, or any adjournment(s) or postponement(s) of the Meeting. This will be a completely virtual meeting, conducted as a live webcast. Further details regarding the Meeting will be provided at a later date.About OraSure TechnologiesOraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA...

Continue reading

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

ONC201 Registrational Trial for Recurrent H3 K27M-mutant GliomaCompelling Response Rates to Date; Defined Regulatory Path to RegistrationPivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 MillionManagement to Host Conference Call at 8:30 a.m. ET TodayDURHAM, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce cell death in multiple cancer types. ONC201...

Continue reading

Loop Insights Selected by bdG Sports to Provide Venue Management Platform to NCAA Big West Conference Championships at Mandalay Bay in Las Vegas

VANCOUVER, British Columbia, Jan. 08, 2021 (GLOBE NEWSWIRE) — Loop Insights Inc. (MTRX:TSXV OTCQB:RACMF) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick and mortar space, is pleased to announce the Company has been selected by bdG Sports to provide its venue management platform to the Big West Conference Men’s and Women’s Basketball Championships being held March 9-13, 2021 at the Mandalay Bay Events Center in Las Vegas.A total of 19 men’s and women’s NCAA basketball teams will compete in the Big West Conference Finals for a chance to enter the NCAA 2020-2021 “March Madness” Tournament in Las Vegas. Loop’s selection to provide its venue management platform at the Big West Conference...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.